SL Science Posts $1.39 Million in First-Half Revenue, Up 22.8%

SL Science Holding Limited posted unaudited first-half 2026 revenue of $1.39 million, up 22.8% year over year, while its net loss widened to $2.16 million over the six-month period.

Revenue for the six months ended June 30 was $1,386,608, compared with $1,129,238 in the same period of 2025. Net loss grew to $2,162,205 from $1,602,089. Basic and diluted net loss per share were each reported as $(0.00); the results did not include a non-GAAP earnings-per-share figure.

Gross profit totaled $557,484, and gross margin rose to 40.2% from 34.5% a year earlier. Revenue came from exosome products. SL Science is a Taiwan-headquartered biomedical company focused on cellular and gene therapies.

CEO William Wang said, “We drove a 23% increase in top-line revenue.”